Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery. Pamela P.
|
|
- Rosalind Griffith
- 5 years ago
- Views:
Transcription
1 Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery Pamela P. Palmer, MD, PhD
2 Disclosures for Dr. Pamela Palmer AcelRx employee Currently own stock and stock options 2 MRC JAN2016
3 Unmet Needs and Rationale for Sublingual Sufentanil 3
4 Pharmacokinetic Limitations of Current IV Opioid Therapy IV morphine Delayed CNS penetration resulting in poor analgesic onset and slow offset which can delay discharge Active metabolite morphine-6-glucuronide can cause delayed side effects 1 IV hydromorphone Slightly more rapid onset than morphine but known for delayed and prolonged side effects (e.g., sedation, respiratory depression) 1 IV fentanyl Rapid brain penetration results in quick onset of analgesia but alpha distribution of this lipophilic drug (1.7 minutes) results in quick offset and requires frequent redosing to maintain analgesia 2,3 1. Lötsch J. J Pain Symptom Manage 2005; 29(5 Suppl):S90-S Scott JC, Cooke JE, Stanski DR. Anesthesiol 1991; 74: MRC JAN Shafer, S and Varvel, J. Anesthesiol 1991; 74:53-63
5 Clinical Need for Rapid-Acting Non- Invasive Analgesic Ambulatory Surgical Centers Allows adequate analgesia while discontinuing IV lines in the process of moving the patient towards discharge readiness Emergency Department IM route Reduced bioavailability during shock Painful to administer IV route Long delays and cost of obtaining IV access Difficult access: obese, elderly and vasoconstricted (e.g., dehydration or shock) patients IV opioid pharmacokinetics not optimal 5 MRC JAN2016
6 Why Sublingual Sufentanil? Sufentanil first synthesized by Janssen in First approved in US for IV delivery in Approved for induction of anesthesia Later approved for epidural delivery as an analgesic in combination with bupivacaine 1 Molecular Properties Lipophilic: 1500 times more fat-soluble than morphine 2 20% non-ionized at physiological ph (fentanyl only 8%) 2 Fat-soluble, non-ionized molecules = more rapid brain penetration than lipid-insoluble, charged molecules 2 1. Stanley TH, Egan TD, Van Aken H. A tribute to Dr Paul AJ Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth. Analgesia. 2008;106(2): MRC JAN De Leon-Casasola et al. Anesth Analg 1996; 83:
7 Sufentanil has Rapid Plasma/ CNS Equilibration (t ½ k e0 ) Commonly used IV opioids have a delayed equilibration time between plasma and CNS t ½ k e0 Morphine 2.8 hrs Morphine t ½ k e0 = 2.8 hours 1 Hydromorphone t ½ k e0 = 46 min 2 Sufentanil rapidly penetrates the CNS due to its very high lipophilicity Sufentanil t ½ k e0 = 6 min 3 Hydromorphone 46 min P-Glycoprotein Plasma Blood Brain Barrier (BBB) Central Nervous System (CNS) 1. Lotsch et al., Anesthesiol 95: , Shafer et al., Geriatric Anesthesiology. 2 nd ed. New York, NY: Springer; Chapter 15:209 28, 2007 MRC JAN Scott et al., Anesthesiol 74:34-42, 1991
8 Plasma Versus Brain Morphine Concentrations Cp\Ce (ng/ml) Delayed brain uptake leads to disconnect between IV dosing and effect 1 Plasma concentrations with IV morphine dosing Morpine + M6G* Plasma Effect Site Morphine/M6G in brain Time (hours) * Assumes equipotency of morphine and M6G; other potency ratios achieved similar results 1. IV PCA dosing frequency based on IAP309 Phase 3 study; plasma and brain concentrations modelled from published plasma 8 MRC JAN2016 and CNS equilibration values by D.Fisher consultant to AcelRx
9 Sufentanil has Rapid Plasma/ CNS Equilibration (t ½ k e0 ) Cp\Ce (pg/ml) Uptake of sublingual sufentanil leads to potential for real-time tracking between dosing and effect 1 Sufentanil Sublingual sufentanil plasma and brain concentrations track together Plasma Effect Site Time (hours) 9 1. Sublingual sufentanil dosing frequency based on IAP309 Phase 3 study; plasma and brain concentrations modelled from published plasma MRC JAN2016 and CNS equilibration values by D.Fisher consultant to AcelRx
10 ARX-04 Clinical Studies Study number Phase # SAP202 Phase 2 dosefinding Clinicaltrials. gov NCT # Patient population Current status of study NCT Bunionectomy Complete/publish ed SAP301 Phase 3 NCT Ambulatory abdominal surgery SAP302 Phase 3 NCT Trauma/injury in the ER SAP303 Phase 3 TBD Ambulatory surgery - All Completed 2015 Recruiting Study Start-up 1. Singla NK, et al. A dose-finding study of sufentanil sublingual microtablets for the management of postoperative 10 MRC JAN2016 bunionectomy pain. J. Trauma. Acute. Care. Surg. 2014;77(3 Suppl 2):S198 S203
11 SAP301 Study Design Postoperative ambulatory surgery patients following abdominal surgery Open herniorrhaphy Abdominoplasty Any laparoscopic abdominal surgery Randomized 2:1, active:placebo Total of 163 randomized and 161 dosed (ITT population) Study completed at 24 hours after first dose These types of surgery are usually outpatient and the patient often discharged by 12 hours Dosing could extend out to 48 hours, if needed Primary efficacy variable: Time-weighted SPID-12 Essentially an area under the curve measurement of the drop in pain intensity from baseline over the first 12 hours of the study 11 MRC JAN2016
12 SAP301 Key Secondary Endpoints Efficacy: TOTPAR: total pain relief as measured on a 0 4 scale (summed) SPRID: summed pain intensity/pain relief composite measure PGA: patient global assessment HPGA: healthcare professional global assessment Safety: Adverse events Vital signs and oxygen saturation Concomitant medications 12 MRC JAN2016
13 SAP301 Results: Demographics Category Category Sex, female, % 68 Surgery, % Age, years, mean 41 Abdominoplasty 50 Race/ethnicity, % Laparoscopic 30 Caucasian 40 Open hernia 20 Hispanic 38 ASA status, % African American Asian BMI <30, % MRC JAN2016
14 SAP301 Patient Disposition ITT population: 107 active; 54 placebo Completed 24 hr: 102 active; 41 placebo Reason for early termination ARX-04 (%) Placebo (%) Adverse event 0 3.7* Lack of efficacy Protocol violation Withdrawal by subject *Two patients in the placebo arm experienced serious adverse events that caused drop-out prior to 24 hours: hemiparesis and syncope. 14 MRC JAN2016
15 SAP301 Results: Primary Endpoint: SPID-12 Pain intensity (PI) measured on a scale of 0 10 (0 = no pain, 10 = worst pain imaginable) Assessment ARX-04 Placebo P-value Baseline PI NS SPID < NS, not significant MRC JAN2016
16 Summed pain intensity difference SAP301 SPID Over First Hour of Treatment (LS Mean) Sufentanil Tablet Placebo Tablet *** *** ** *** **P<0.01, ***P< Time (minutes) 16 MRC JAN2016
17 SAP301 Key Secondary 12-Hour & 24-Hour Endpoints Endpoint ARX-04 Placebo P-value TOTPAR <0.001 SPRID <0.001 SPID <0.001 TOTPAR SPRID <0.001 PGA-24 a <0.001 HPGA-24 a <0.001 a Percent of patients reporting good or excellent. 17 MRC JAN2016
18 SAP301 Number of ARX-04 Tablets Dosed Time period Number of tablets, median (range) Interdosing interval, mean 0 12 Hours 4 (1 9) 185 minutes 0 24 Hours 7 (1 15) 221 minutes 18 MRC JAN2016
19 SAP301 Adverse Events (>3% in either group) No statistical difference for ARX-04 compared to placebo Adverse Event, % ARX-04 Placebo No Adverse Event Nausea Headache Vomiting Dizziness Hypotension Flatulence Somnolence Procedural nausea Pruritus MRC JAN2016
20 Conclusions Efficacy and tolerability results from this study suggest that sufentanil 30 mcg tablets dispensed sublingually via single-dose applicator may offer a viable alternative to IM or IV dosing in an ambulatory surgery population Nausea and headache were the most commonly reported AEs for both treatment arms Additional studies are indicated to assess potential applications within emergency medicine or other medically supervised venues 20 MRC JAN2016
21 Thank You 21
Phase 3 Efficacy and Safety Results of Sufentanil Sublingual Tablet
Phase 3 Efficacy and Safety Results of Sufentanil Sublingual Tablet 2016 MHSRS Plenary Session Pamela Palmer, MD PhD Chief Medical Officer, AcelRx Pharmaceuticals, Inc. Treatment Considerations for Battlefield
More informationPhase 3 Efficacy and Safety Results of the Sufentanil Sublingual Tablet 30 mcg (DSUVIA )
Phase 3 Efficacy and Safety Results of the Sufentanil Sublingual Tablet 30 mcg (DSUVIA ) 2017 SOMSA Plenary Session Mark Evashenk VP Clinical Affairs, AcelRx Pharmaceuticals, Inc. Challenges with Management
More informationPain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System
Pain Management after Major Orthopedic Surgery with the Sufentanil Sublingual Microtablet System David W. Griffin, MD Vero Beach, FL Disclosures/Acknowledgements Dr. Griffin received research funding and
More informationSufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type
Sufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type 2016 European Society of Regional Anesthesia Congress Maastricht,
More informationAcelRx Pharmaceuticals. Corporate Presentation First Quarter 2016
AcelRx Pharmaceuticals Corporate Presentation First Quarter 2016 Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the
More informationAcelRx Pharmaceuticals. Corporate Presentation June 2016
AcelRx Pharmaceuticals Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to the process
More informationForward Looking Statements
September 2015 Forward Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to future financial results including AcelRx s plans to
More informationSingle- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers
Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers Pamela P. Palmer, MD, PhD AcelRx Pharmaceuticals, Inc. October 20, 2009 1 Sufentanil: A Superior Opioid Approved
More informationCorporate overview. December Exploring innovative solutions for acute pain
Corporate overview December 2017 Exploring innovative solutions for acute pain Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationSufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study
ORIGINAL ARTICLE Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study Harold S. Minkowitz, MD*; David Leiman, MD ;
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationCorporate Overview. March 2018
Corporate Overview March 2018 Forward looking statements This presentation contains forward looking statements, including, but not limited to, statements related to financial results and trends; the process
More informationCorporate overview. September Exploring innovative solutions for acute pain
Corporate overview September 2017 Exploring innovative solutions for acute pain Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationI.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results
I.V. CR845 Adaptive Phase 2/3 Post Operative Pain Study Results A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of I.V. CR845
More informationA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model Neil
More informationSufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty
Sufentanil Sublingual Tablet System for the Management of Postoperative Pain after Knee or Hip Arthroplasty A Randomized, Placebo-controlled Study Maurice Jove, M.D., David W. Griffin, M.D., Harold S.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationAnalgesia is a labeled indication for all of the approved drugs I will be discussing.
Comparative Opioid Pharmacology Disclosure Analgesia is a labeled indication for all of the approved drugs I will be discussing. I ve consulted with Glaxo (remifentanil), Abbott (remifentanil), Janssen
More informationHTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy
HTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy Eugene Viscusi, 1 Oscar DeLeon-Casasola, 2 TJ Gan,
More informationHTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018
HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies June 21, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationHTX-011 Postoperative Pain Program Topline Results From Phase 3. March 19, 2018
HTX-011 Postoperative Pain Program Topline Results From Phase 3 March 19, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBalanced Analgesia With NSAIDS and Coxibs. Raymond S. Sinatra MD, Ph.D
Balanced Analgesia With NSAIDS and Coxibs Raymond S. Sinatra MD, Ph.D Prostaglandins and Pain The primary noxious mediator released from damaged tissue is prostaglandin (PG) PG is responsible for nociceptor
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationUse of Pregabalin for Postoperative Pain: Outcomes in 2 Trials
Use of Pregabalin for Postoperative Pain: Outcomes in 2 Trials Jacques E. Chelly, 1 Neil Singla, 2 David R. Lionberger, 3 Henrik Kehlet, 4 Luis Sanin, 5 Jonathan Sporn, 5 Ruoyong Yang, 5 Raymond C. Cheung,
More informationSatisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
More informationPerioperative Pain Management
Perioperative Pain Management Overview and Update As defined by the Anesthesiologist's Task Force on Acute Pain Management are from the practice guidelines from the American Society of Anesthesiologists
More informationOP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4
Opioid MCQ OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4 OP02 [Mar96] Which factor does NOT predispose to bradycardia with
More informationEffective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1
Effective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1 Fast onset of pain relief with 7% reduction in visual analog scale (VAS) scores
More informationComparison of fentanyl versus fentanyl plus magnesium as post-operative epidural analgesia in orthopedic hip surgeries
Original Research Article Comparison of fentanyl versus fentanyl plus magnesium as post-operative epidural analgesia in orthopedic hip surgeries P V Praveen Kumar 1*, Sreemanth 2 1 Associate Professor,
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationCompany Update. June 24, 2018
Company Update June 24, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationThe intensity of preoperative pain is directly correlated with the amount of morphine needed for postoperative analgesia
The intensity of preoperative pain is directly correlated with the amount of morphine needed for postoperative analgesia This study has been published: The intensity of preoperative pain is directly correlated
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationTAP blocks vs wound infiltration in laparoscopic colectomies Results of a Randomised Controlled Clinical Trial
TAP blocks vs wound infiltration in laparoscopic colectomies Results of a Randomised Controlled Clinical Trial Kim Gorissen Frederic Ris Martijn Gosselink Ian Lindsey Dept of Colorectal Surgery Dept of
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationA randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in
A randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in patients using i.v. patient-controlled analgesia (PCA) for
More informationBird M : Acute Pain Management: A New Area of Liability for Anesthesiologist. ASA Newsletter 71(8), 2007.
Citation Bird M : Acute Pain Management: A New Area of Liability for Anesthesiologist. ASA Newsletter 71(8), 2007. Full Text A 71-year-old obese female smoker with hypertension and diabetes underwent a
More informationWhat s New in Post-Cesarean Analgesia?
Anesthesia & Obstetrics What s New in Post-Cesarean Analgesia? October 23rd, 2013 2013 UCSF What Does The Evidence Tell Us? Mark Rollins, MD, PhD UC SF Post-Delivery Pain (Mean pain scores for first 24
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationEXPAREL. An Innovative Non-Opioid Option for the Management of Postsurgical Pain. Presenter s Name Affiliation Date
EXPAREL An Innovative Non-Opioid Option for the Management of Postsurgical Pain Presenter s Name Affiliation Date Disclosures The speaker has a consulting relationship with Pacira Pharmaceuticals, Inc.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRichard A. Beers, M.D. Professor, Anesthesiology SUNY Upstate Medical Univ VA Medical Center Syracuse, NY
Richard A. Beers, M.D. Professor, Anesthesiology SUNY Upstate Medical Univ VA Medical Center Syracuse, NY beersr@verizon.net 2 Improvements in safety and advances in care are re-invested in older, sicker
More informationShow Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital
Show Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital Overview Review overall (ERAS and non-eras) data for EA, PVB, TAP Examine
More informationCompany Update. August 8, 2018
Company Update August 8, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationNew Methods for Analgesia Delivery
New Methods for Analgesia Delivery Guy Ludbrook MBBS PhD FANZCA Royal Adelaide Hospital and University of Adelaide South Australia Anesthesiology is on the verge of a major evolution that will involve
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationPost Caesarean Analgesia An Update. Kim Ekelund MD, PhD, associate professor Rigshospitalet Copenhagen, Denmark
Post Caesarean Analgesia An Update Kim Ekelund MD, PhD, associate professor Rigshospitalet Copenhagen, Denmark Post caesarean analgesia No Conflicts of Interests Neuraxial opioids Multimodal therapy Plan
More informationScottish Medicines Consortium
Scottish Medicines Consortium fentanyl 50 micrograms / dose, 100 micrograms/dose, 200 micrograms / dose nasal spray (Instanyl ) No. (579/09) Nycomed UK Ltd 09 October 2009 The Scottish Medicines Consortium
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMerja Kokki MD, PhD Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, School of Medicine, University of Eastern Finland
Long-acting opioids in obstetric analgesia and the newborn Merja Kokki MD, PhD Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, School of Medicine, University of Eastern Finland
More informationDisclosure. Objectives 9/13/2018. NIA/NIH 1R03AG (PI-Bentov) More than Start low go slow. start low go slow
Sedation and analgesia in geriatric trauma Sept 2018 Itay Bentov MD PhD Disclosure NIA/NIH 1R03AG042353 (PI-Bentov) More than Start low go slow start low go slow Objectives List age-related physiologic
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationDigital RIC. Rhode Island College. Linda M. Green Rhode Island College
Rhode Island College Digital Commons @ RIC Master's Theses, Dissertations, Graduate Research and Major Papers Overview Master's Theses, Dissertations, Graduate Research and Major Papers 1-1-2013 The Relationship
More informationIntravenous Dezocine for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine
Intravenous for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine Uma A. Pandit, MD, S aria P. Kothary, MD, and Sujit K. Pandit, MD, PhD, a new mixed agonist-antagonist opioid
More informationRichard Smiley, MD, PhD Virginia Apgar MD Professor of Anesthesiology Chief, Obstetric Anesthesia Columbia University Medical Center New York, NY,
Richard Smiley, MD, PhD Virginia Apgar MD Professor of Anesthesiology Chief, Obstetric Anesthesia Columbia University Medical Center New York, NY, USA Disclosures Off label use: Fentanyl, Sufentanil IT
More informationIntravenous lidocaine infusions. Dr Ian McConachie FRCA FRCPC
Intravenous lidocaine infusions Dr Ian McConachie FRCA FRCPC Thank the organisers for inviting me. No conflicts or disclosures Lidocaine 1 st amide local anesthetic Synthesized in 1943 by Lofgren in Sweden.
More informationInitiating Labour Analgesia in 2020: Predicting the Future Epidurals, CSEs, Spinal Catheters, Epidrum & Epiphany
Initiating Labour Analgesia in 2020: Predicting the Future Epidurals, CSEs, Spinal Catheters, Epidrum & Epiphany Kenneth E Nelson, M.D. Associate Professor Wake Forest University, North Carolina, USA Initiating
More informationCompany Update F e b r u a r y
Company Update February 2017 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationPAIN PODCAST SHOW NOTES:
PAIN PODCAST SHOW NOTES: Dallas Holladay, DO Ultrasound Fellow Cook County Hospital Rush University Medical Center Jonathan D. Alterie, DO PGY-2, Emergency Medicine Midwestern University An overview of
More informationOBSTETRICS Intrathecal morphine reduces breakthrough pain during labour epidural analgesia
British Journal of Anaesthesia 98 (2): 241 5 (2007) doi:10.1093/bja/ael346 Advance Access publication January 8, 2007 OBSTETRICS Intrathecal morphine reduces breakthrough pain during labour epidural analgesia
More informationAssistant Professor, Anaesthesia Department, Govt. General Hospital / Guntur Medical College, Guntur, Andhra Pradesh, India.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 8 Ver. I (August. 2016), PP 87-91 www.iosrjournals.org A Comparative Study of 0.25% Ropivacaine
More informationAcute Pain Management in the Opioid Tolerant Patient. Objectives. Opioids. The participant will be able to define opioid tolerance
Acute Pain Management in the Opioid Tolerant Patient Kathleen M. Colfer, MSN, RN-BC Clinical Nurse Specialist Acute Pain Management Service Department of Anesthesiology Thomas Jefferson University Hospital
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI NOV 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationRemifentanil. Addressing the challenges of ambulatory orthopedic procedures 1-3
Remifentanil Addressing the challenges of ambulatory orthopedic procedures 1-3 INDICATIONS AND IMPORTANT RISK INFORMATION INDICATIONS ULTIVA (remifentanil HCl) for Injection is indicated for intravenous
More informationChapter 25. General Anesthetics
Chapter 25 1. Introduction General anesthetics: 1. Analgesia 2. Amnesia 3. Loss of consciousness 4. Inhibition of sensory and autonomic reflexes 5. Skeletal muscle relaxation An ideal anesthetic: 1. A
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDaniel Canafax, PharmD VP, Clinical Research Theravance, Inc.
Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a Phase 2b Study of Patients with Opioid-Induced Constipation (OIC) Ross Vickery, PhD, 1 Yu-Ping Li, PhD, 1 Ullrich Schwertschlag,
More informationGabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement. Manyat Nantha-Aree, MD
Gabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement Manyat Nantha-Aree, MD Objective n Preliminary results of MOBILE study in total hip and knee arthroplasty Background n Gabapentin=
More informationComparison of Bolus Bupivacaine, Fentanyl, and Mixture of Bupivacaine with Fentanyl in Thoracic Epidural Analgesia for Upper Abdominal Surgery
Original Article DOI: 10.17354/ijss/2016/156 Comparison of Bolus Bupivacaine, Fentanyl, and Mixture of Bupivacaine with Fentanyl in Thoracic Epidural Analgesia for Upper Abdominal Surgery Sachin Gajbhiye
More informationOFIRMEV a non-opioid, non-nsaid, intravenous analgesic for the management of pain
FOR PHARMACY PROFESSIONALS In pharmacokinetic studies Rapid time to reach Cmax with IV acetaminophen OFIRMEV from the start OFIRMEV g demonstrated early and high Cmax at minutes Consider administering
More informationPatient Safety - IV Opioid Use in Hospitalized Patients. October 2014
Patient Safety - IV Opioid Use in Hospitalized Patients October 2014 Objectives List reasons that necessitated development of risk assessment State a few risk factors or medical conditions from the IV
More informationResponding to The Joint Commission Alert on Safe Use of Opioids in Hospitals
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures
More informationLabor Epidural: Local Anesthetics and Beyond
Goals: Labor Epidural: Local Anesthetics and Beyond Pedram Aleshi MD The Changing Practice of Anesthesia September 2012 Review Concept of MLAC Local anesthetic efficacy Local anesthetic sparing effects:
More information1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective
Cancer Related Pain: Case-Based Pharmacology Jeannine M. Brant, PhD, APRN, AOCN Oncology Clinical Nurse Specialist Nurse Scientist Billings Clinic Conflicts of Interest Jeannine Brant has served on the
More informationFentanyls and Naloxone. Opioids, Overdose, and Naloxone
Opioids, Overdose, and Naloxone Presenter Disclosure Presenter s Name: Michael Beazely I have no current or past relationships with commercial entities Speaking Fees for current program: I have received
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStatistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue
STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationIntraspinal (Neuraxial) Analgesia Community Nurses Competency Test
Intraspinal (Neuraxial) Analgesia Community Nurses Competency Test 1 Intraspinal (Neuraxial) Analgesia for Community Nurses Competency Test 1) Name the two major classifications of pain. i. ii. 2) Neuropathic
More informationAppendix D: Drug Tables
Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic
More informationMr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government
Mr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government Introduction Brief update Two main topics Use of Gabapentin Local Infiltration Analgesia
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationReview Polyanalgesic Consensus Charles Brooker Royal North Shore Hospital
Review Polyanalgesic Consensus 2007 Charles Brooker Royal North Shore Hospital cbrooker@med.usyd.edu.au Article review Polyanalgesic Consensus Conference 2007 Recommendations for the management of Pain
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationOrthostatic Intolerance Ambulation in Patients Using Patient Controlled Analgesia
Original Article Korean J Pain 2013 July; Vol. 26,. 3: 277-285 pissn 2005-9159 eissn 2093-0569 http://dx.doi.org/10.3344/kjp.2013.26.3.277 Orthostatic Intolerance Ambulation in Patients Using Patient Controlled
More informationNerve Blocks & Long Acting Analgesia for Plastic Surgeons. Karol A Gutowski, MD, FACS
Nerve Blocks & Long Acting Analgesia for Plastic Surgeons Karol A Gutowski, MD, FACS Disclosures None related to this topic Why is Non-Opioid Analgesia Important Opioid epidemic Less opioid use Less PONV
More informationI ve Got You Under My Skin: A Comparison of IV and s/c PCA. Nick Williamson Clinical Nurse Specialist
I ve Got You Under My Skin: A Comparison of IV and s/c PCA Nick Williamson Clinical Nurse Specialist How did PCA get under my skin? Started in 2009 when I started working at KCH Subcut PCA!!! PCA refers
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCOMPARISON OF EPIDURAL BUTORPHANOL VERSUS EPIDURAL MORPHINE IN POSTOPERATIVE PAIN RELIEF
COMPARISON OF EPIDURAL BUTORPHANOL VERSUS EPIDURAL MORPHINE IN POSTOPERATIVE PAIN RELIEF Geeta P. Parikh *, Shah Veena R **, Kalpana Vora ***, Beena Parikh *** and Anish Joshi **** Abstract Introduction:
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More information